Captisol-enabled busulfan - Ligand Pharmaceuticals

Drug Profile

Captisol-enabled busulfan - Ligand Pharmaceuticals

Alternative Names: CE-Busulfan

Latest Information Update: 19 Oct 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ligand Pharmaceuticals
  • Developer Ligand Pharmaceuticals; University of Kansas
  • Class Antineoplastics; Butylene glycols; Glycols; Mesylates; Myeloablative agonists; Small molecules
  • Mechanism of Action Alkylating agents; DNA cross linking agents; DNA synthesis inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Haematological malignancies

Highest Development Phases

  • Preclinical Haematological malignancies

Most Recent Events

  • 01 Sep 2015 Captisol-enabled busulfan is available for licensing as of 01 Sep 2015. http://www.ligand.com/
  • 01 Sep 2015 Preclinical trials in Haematological malignancies in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top